Bavarian Nordic
Mr. May joined Bavarian Nordic in January 2020 from GlaxoSmithKline (GSK), where he served as vice president and global vaccines commercialization leader and was responsible for global strategic leadership and performance of several lifesaving vaccines, including Rabipur/RabAvert and Encepur, which Bavarian Nordic acquired from GSK in 2019. Mr. May holds a PharmD and MBA. He is a French national, born in 1967.
This person is not in any teams
This person is not in any offices
Bavarian Nordic
8 followers
Bavarian Nordic A/S is a biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases.